key: cord-1013128-gpwp691s
authors: Yadav, Pragya D.; Sapkal, Gajanan N.; Sahay, Rima R.; Patil, Deepak Y.; Deshpande, Gururaj R.; Jain, Rajlaxmi; Nyayanit, Dimpal A.; Shete, Anita M.; Suryawanshi, Annasaheb; Nandapurkar, Ashok; Gurav, Yogesh K.; Abraham, Priya
title: Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees
date: 2022-03-19
journal: J Infect
DOI: 10.1016/j.jinf.2022.03.016
sha: 01db19c4f501e8682ca02e6b4fabd6dce4ae6ea0
doc_id: 1013128
cord_uid: gpwp691s

nan

The GMT titres of IgG and NAb clearly demonstrate highest immune response amongst breakthrough cases followed by recovered and naïve cases. Omicron was less effectively neutralized with the sera of naïve cases (12.9 fold) than recovered (7.98 fold) and breakthrough (8.84 fold) compared to B.1 (Figure 2 A-C) . Although, the immune response was less against the Omicron, it would still protected the individuals from developing severe disease, hospitalization and mortality.

It is well known that the higher humoral and cellular immune response helps the 

Authors do not have a conflict of interest among themselves. 

Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections or vaccinees

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Antibody titers and breakthrough infections with Omicron SARS-CoV-2

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients

The authors would like to gratefully acknowledge the staff of ICMR-NIV, Pune including Mrs. Asha Salunkhe, Mr. Chetan Patil, Mrs. Priyanka Waghmare, Mrs. Poonam Bodke, Mrs.Shilpa Ray for extending the excellent technical support. We thank to all study participants.